Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CEO Chris Bunka was Interviewed on Uptick Network Discussing Company’s Positive Future Progress

Posted on: 10 Aug 17

Kelowna, BC , Aug. 10, 2017 (GLOBE NEWSWIRE) -- CEO Chris Bunka was Interviewed on Uptick Network Discussing Company’s Positive Future Progress


Kelowna, BC (UPTICK Newswire – August 10, 2017) -  Lexaria Bioscience Corp. (OTC:LXRP) CEO Chris Bunka was interviewed on the Uptick Network Stock Day Radio Show with host Everett Jolly. Mr. Bunka updates the Uptick Network on the overall accomplishments that have presented itself in the past 3 months. Mr. Bunka further discusses the outlook for shareholders, their expectations for the company’s profitability and where the company is at in this progress. R&D could open the NSAID and Nicotine markets to Lexaria and with significant increase in corporate revenues, additional expansion is ahead.


In closing CEO, Chris Bunka states, “In the next 12 months you won’t even recognize Lexaria. If you look at it today and look at where we are going to be in the next 12 months… I think we are going to be an entirely different company.”


The interview was paid by Lexaria Bioscience Corp and approved by Chris Bunka. The distribution was sent out to the Uptick Network Stock Day Podcast, sponsors, its affiliates and social media distribution platforms.

To listen to the interview please click here or the following link:

About Lexaria
Lexaria Bioscience Corp. is a biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been proven to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

For more information, visit

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Lexaria Bioscience Corp. 
Alex Blanchard
Communications Manager
(778) 796-1897 

CONTACT: Lexaria Bioscience Corp. Alex Blanchard Communications Manager (778) 796-1897 GlobeNewswire

Last updated on: 11/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.